Efficacy and safety of desloratadine combined with dipyridamole in the treatment of chronic urticaria

Journal of the European Academy of Dermatology and Venereology

Volumn 22, Issue 4, 2008, Pages 487-492

  Khalaf, A T ^a   Liu, X M ^a   Sheng, Wan Xiang ^a   Tan, J Q ^a   Abdalla, A N ^a  

^a WUHAN UNIVERSITY   (China)

Author keywords

Chronic urticaria (CU); Desloratadine; Dipyridamole; F1+2

Indexed keywords

CORTICOSTEROID; DESLORATADINE; DILULEITADING PIAN; DIPYRIDAMOLE; PLACEBO; PROTHROMBIN; PROTHROMBIN FRAGMENT F1 + F2; SHUANGMIDAMO PIAN; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; AUTOIMMUNE DISEASE; CHILD; CHRONIC URTICARIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNOPATHOGENESIS; INFANT; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SIDE EFFECT; SKIN TEST; TREATMENT DURATION; WITHDRAWAL SYNDROME; XEROSTOMIA;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; DIPYRIDAMOLE; DRUG THERAPY, COMBINATION; FEMALE; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; LORATADINE; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; SKIN TESTS; TREATMENT OUTCOME; URTICARIA;

EID: 41149177052     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2007.02511.x     Document Type: Article

References (27)

1. Greaves MW. Chronic urticaria. N Engi I Med 1995; 332: 1767-1772.
2. Kobza-Black A. Guide to recognition and management of urticaria. Prescril; Proc 1997; 5: 25-25.
3. Greaves MW, O'Donnell BR. Not all chronic urticaria is idiopathic. Exp Dermatol 1998; 7: 11-13.
4. Doutre M, Physiopathology of urticaria. Eur J Dermatol 1999; 9: 601-605.
5. Grattan C, Eh Dawn G, Gibbs S, Francis DM. Blood basophil numbers in chronic ordinary urticaria and healthy controls: Diurnal variation, influence of loratadine and prednisolone and relationship to disease activity. Clin Exp Allergy 2003; 33: 337-341.
6. Ormerod AD. Urticaria. Recognition, causes and treatment. Drugs 1994; 48: 717-730.
7. Simons FER. The therapeutic index of newer HI-receptor antagonists. Clin Exp Allerg 1994; 24: 707-723.
8. Simons FER. HI Receptor antagonists. Comparative tolerability and safety. Drug Safety 1994; 10: 350-380.
9. Zuberbier T, Bindslev-Jensen C, Canonica W et al. EAACI/GA 2 LEN/EDF guideline: Management of urticaria. Allergy 2006; 61: 321-331.
10. Bachert C. Therapeutic points of intervention and clinical implications: role of desloratadine. Allergy 2002; 57(Suppl. 75): 13-18.
11. Henz BM. The pharmacologic profile of desloratadine: A review. Allergy 2001; 56: 7-13.
12. Zuberbier T, Bindslev-Jensen C, Canonica W et al. EAACI/GA 2 LEN/EDF guideline: Definition, classification and diagnosis of urticaria. Allergy 2006; 61: 316-320.
13. Figueiredo A, Ribeiro CA, Goncalo M, Almeida L, Poiares-Baptista A, Teixeira F. Mechanism action of doxepin in the treatment of chronic urticaria. Fundam Clin Pharmacol 1990; 4: 147-158.
14. Brestel EP, Thrush LB. The treatment of glucocorticosteroid dependent chronic urticaria with sanazolol. J Allerg Clin Immunol 1988; 82: 265-269.
15. Bressler RB, Sowel K, Huston DP. Therapy of chronic idiopathic urticaria with nifedipine demonstration of beneficial effect in a double-blinded, placebo-controlled, crossover trial. J Allerg Clin Immunol 1989; 83: 756-763.
16. Monroe EW. Treatment of urticaria. Dermatol Clin 1985; 4: 51-55.
17. Draberova L. Cyclosporine A inhibits rat mast cell activation. Eur J Immunol 1990; 20: 1469-1473.
18. Parslew R, Pryce D, Ashworth J, Friedmann PS. Warfarin treatment of chronic idiopathic urticaria and angio-oedema. Clin Exp Allergy 2000; 30: 1161-1165.
19. Chua SL, Gibbs S. Chronic urticaria responding to subcutaneous heparin sodium. Br J Dermatol 2005; 153: 216.
20. 1+2 fragment and thrombin-antithrombin complex. Blood 1982; 59: 1086-1095.
21. Soria J, Soria C, Mirshahi M, Samama M. Markers of fibrinogen derivatives used in clinical investigation. Semin Thromb Hemost 1985; 11: 129-132.
22. Gershlick A. Are there markers of the blood-vessel wall interaction and of thrombus formation that can be used clinically? Circulation 1990; 81 (Suppl. I): I-28-I-34.
23. 1+2 and intensity of treatment with oral anticoagulants. Thromb Haemost 1991; 66: 741. Letter.
24. Asero R, Tedeschi A, Riboldi P, Cugno M. 'Plasma of patients with chronic urticaria shows signs of thrombin generation, and its intradermal injection causes wheal-and-flare reactions much more frequently than autologous serum'. J Allergy Clin Immunol 2006; 117: 1113-1117, Epub 2006 February 14.
25. Brindley LL, Sweet JM, Goetzl EJ. Stimulation of histamine release from human basophils by humanplatelet factor 4. J Clin Invest 1983; 72: 1218-1223.
26. Suzuki R, Kimura T, Kitaichi K. et al. Platelet factor 4 fragment induces histamine release from rate peritoneal mast cells. Peptides 2002; 23: 1713-1717.
27. Masini E, Di Bello MG, Raspanti S. et al. The role of histamine in platelet aggregation by physiological and immunological stimuli. Inflamm Res 1998; 47: 211-220.